ANRS, Emerging Infectious Diseases: all 215 studies

Page 2 of 3. Open to participants first (38), then studies with results posted, then the rest; newest registration first within each.

• Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected PatientsStatus unknownNCT03941210
• Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive InterventionCompletedNCT03870438Phase 3
• Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEVStatus unknownNCT03869944Phase 2
• ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in MaliStatus unknownNCT03795415
• Evaluation of Triage Options After HPV Testing for Cervical Cancer Screening Among HIV-infected WomenStatus unknownNCT03789513Not applicable
• HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV ExposureCompletedNCT03642704Phase 4
• Role of the IL33/Amphiregulin Pathway as a Potential Therapeutic Target in HIV InfectionStatus unknownNCT03622177
• Evaluation of Third-line cART Regimen in Cambodia (3DICAM)Status unknownNCT03602690Phase 2
• DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)CompletedNCT03537196Phase 4
• Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & SafetyCompletedNCT03519503
• "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in EgyptStatus unknownNCT03510637
• Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)CompletedNCT03459157Not applicable
• ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)Status unknownNCT03354936
• Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCVCompletedNCT03324633
• National Cohort of Children Born to HIV-positive MothersStatus unknownNCT03306251
• A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32aCompletedNCT03298360
• Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected PatientsCompletedNCT03256422Phase 3
• Cohort of HIV-infected ChildrenCompletedNCT03235258
• Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, SenegalCompletedNCT03215732
• Cohort of Patients Naive of Antiretroviral Treatment at EnrollmentCompletedNCT03137797
• Prevention of HIV in "Île-de-France"Status unknownNCT03113123Not applicable
• Methylphenidate for Cocaine DependenceWithdrawnNCT03090269Phase 2
• PoC-HCV Genedrive Viral Detection Assay Validation StudyCompletedNCT02992184
• National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) InfectionCompletedNCT02987530Phase 3
• An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic InfectionTerminatedNCT02972450Phase 1/2
• Tenofovir As Prevention Of Hepatitis b Mother-to-child TransmissionStatus unknownNCT02937779Phase 4
• Gut-Associated Lymphocyte TraffickingCompletedNCT02906137Not applicable
• Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular ImmunityCompletedNCT02886416
• Investigative Mathematical Modeling of Hospital Transmission of Hepatitis CStatus unknownNCT02826447
• Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited SettingsCompletedNCT02777229Phase 3
• Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase InhibitorsCompletedNCT02738502Phase 2
• CLEAC (Comparison of Late Versus Early Antiretroviral Therapy in HIV-infected Children)Status unknownNCT02674867Not applicable
• Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedNCT02647632Phase 2
• Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan AfricaCompletedNCT02626286Not applicable
• Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDSStatus unknownNCT02624453Not applicable
• Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional StudyCompletedNCT02592174Not applicable
• Evaluation of an Innovative Tuberculosis Diagnostic TestStatus unknownNCT02573623
• A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)Status unknownNCT02570334Not applicable
• Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-FranceCompletedNCT02566148
• A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)CompletedNCT02527096Phase 2
• Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central AfricaCompletedNCT02405013Phase 2
• Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 PatientsCompletedNCT02384967Phase 2
• Qualification of Point-of-Care Assays for Management of HCV PatientsStatus unknownNCT02335320
• Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B VaccinationCompletedNCT02323308
• Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin RegimenWithdrawnNCT02309450Phase 2
• Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With MenCompletedNCT02287961Not applicable
• Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT02273765Phase 3
• Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)TerminatedNCT02247687Phase 3
• Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan AfricaCompletedNCT02192658
• 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV PatientsCompletedNCT02157311Phase 3
• First-Line Treatment for HIV-2CompletedNCT02150993Phase 2/3
• Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infectionCompletedNCT02125500Phase 2
• Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive PatientsCompletedNCT02116374
• Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)CompletedNCT02107365Phase 2
• Evaluation of the National Treatment Program of Hepatitis C in EgyptWithdrawnNCT02101177
• Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis CWithdrawnNCT02099604Phase 3
• Evaluation of Raltegravir During the Third Trimester of PregnancyCompletedNCT02099474Phase 2
• Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected PatientsCompletedNCT02093754Not applicable
• Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3CompletedNCT02057796Phase 4
• Outcome at 5 Years of Early Treated HIV Infected Infants in the PEDIACAM ProjectActive, not recruitingNCT02043418
• Third Line Antiretroviral Treatment Optimization in Sub-Saharan AfricaStatus unknownNCT02025868Phase 2
• Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infectionStatus unknownNCT01986543Phase 2
• Therapeutic Option for Hepatitis B and C: a French CohortStatus unknownNCT01953458
• X-linked Biological Response to HIV Sensing: the ANRS EP 53 StudyCompletedNCT01952587Not applicable
• Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) InfectionStatus unknownNCT01944527
• IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV InfectionCompletedNCT01942655Not applicable
• Early Identification and Treatment of Early HIV Infection in Côte d'IvoireCompletedNCT01917175
• Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in AfricaCompletedNCT01905059Phase 3
• Epicardial Adipose Tissue And Coronary Risk In HIV-Infected PatientsCompletedNCT01899196Not applicable
• Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?CompletedNCT01895920Not applicable
• Prevalence of Histoplasmosis in HIV + Patients with a Rapid Diagnostic Test in West IndiesCompletedNCT01884779
• National Evaluation of PI-based 2nd Line Efficacy in CambodiaCompletedNCT01801618
• Nutritional and Metabolic Disorders in HIV Infected Children and AdolescentCompletedNCT01771562
• Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null RespondersCompletedNCT01725542Phase 2
• Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan AfricaStatus unknownNCT01715922Phase 2/3
• Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy WomenTerminatedNCT01715103Not applicable
• Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV)Status unknownNCT01545544
• French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and RibavirinCompletedNCT01514890
• Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidenceCompletedNCT01509508Not applicable
• Lipopeptide Immunisation With GTU-multiHIV TrialCompletedNCT01492985Phase 2
• On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With MenCompletedNCT01473472Phase 3
• Renal Transplantation and Raltegravir in HIV-Infected PatientsCompletedNCT01453192Phase 3
• Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With LipohypertrophyTerminatedNCT01420523Phase 2
• Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected PatientsCompletedNCT01348308Phase 3
• Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/RibavirinCompletedNCT01335529Phase 2
• Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedNCT01332955Phase 2
• Improving Diagnosis of Tuberculosis in HIV Infected Children in Asia (Cambodia, Vietnam)and Africa (Burkina Faso, Cameroon)CompletedNCT01331811Not applicable
• A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/RitonavirWithdrawnNCT01255371Phase 3
• Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot StudyCompletedNCT01207986Not applicable
• A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis BStatus unknownNCT01172392Phase 3
• Cohort of HIV Associated LymphomasCompletedNCT01164436
• Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of AgeCompletedNCT01127204Phase 2/3
• Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve SubjectsCompletedNCT01066962Phase 3
• Residual Replication of HIV-1 in the Gut Associated Lymphoid Tissue (GALT) of Patients on Highly Active Antiretroviral Therapy (HAART): the ANRS EP 44 StudyCompletedNCT01038401Not applicable
• Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
• Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCompletedNCT01022476Phase 1/2
• Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedNCT01010646Phase 2
• Efficacy and Safety of Varenicline Among HIV-infected PatientsCompletedNCT00918307Phase 3
• ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIVCompletedNCT00901524Phase 2
• Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active TuberculosisCompletedNCT00822315Phase 2

← ANRS, Emerging Infectious Diseases overview and focus areas